Compare PSIX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSIX | NVCR |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | PSIX | NVCR |
|---|---|---|
| Price | $86.27 | $10.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $98.76 | $26.42 |
| AVG Volume (30 Days) | 407.9K | ★ 1.4M |
| Earning Date | 03-13-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.27 | N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $675,481,000.00 | $642,269,000.00 |
| Revenue This Year | $50.35 | $10.64 |
| Revenue Next Year | $20.10 | $5.37 |
| P/E Ratio | $15.88 | ★ N/A |
| Revenue Growth | ★ 54.78 | 11.17 |
| 52 Week Low | $18.10 | $9.82 |
| 52 Week High | $121.78 | $22.95 |
| Indicator | PSIX | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 62.31 | 30.78 |
| Support Level | $65.96 | $9.82 |
| Resistance Level | $87.50 | $10.64 |
| Average True Range (ATR) | 6.44 | 0.60 |
| MACD | 0.94 | -0.28 |
| Stochastic Oscillator | 93.33 | 14.49 |
Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that run on nondiesel fuels, including natural gas, propane, and gasoline. The company's products are designed to meet emission standards imposed by environmental regulatory bodies like the Environmental Protection Agency. Its products are distributed to a wide range of industrial original equipment manufacturers that supply equipment to sectors including power generation, oil and gas, material handling, airport ground support, agricultural, turf, construction and irrigation. The company generates majority of its sales from United States.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.